Year-end Sale % OFF 
Abstract
Challenges facing COVID-19 vaccination in India: Lessons from the initial vaccine rollout.
Highlights
Abhishek Pandey1*, Pratha Sah1*, Seyed M Moghadas2, Sandip Mandal3, Sandip Banerjee4, Peter J Hotez5, Alison P Galvani1
In an attempt to control the COVID-19 pandemic, India initially authorized the emergency use of two vaccines, each requiring two doses – Covishield developed by Oxford/AstraZeneca and Covaxin developed by Bharat Biotech in collaboration with Indian Council for Medical Research (ICMR) and the National Institute of Virology The vaccination drive in India started on January 16, 2021 with an ultimate target of vaccinating 300 million people by August 2021 [2]
We calculated the rate of vaccine uptake for each state by estimating the percentage of eligible individuals registered for vaccination and using data of those receiving at least the first dose of vaccine by the end of the first vaccination phase
Summary
Percentage vaccinated galand, Punjab, Goa, Mizoram and Tamil Nadu. By the end of February 2021, only four states (Gujarat, Rajasthan, Chhattisgarh and Uttarakhand) were able to vaccinate at least half of those eligible with the first dose. Less than 20% of eligible individuals were vaccinated in the states of Nagaland, Punjab, Tamil Nadu, Mizoram, Goa, and Manipur. The states of Maharashtra, Kerala, Karnataka, Punjab and Tamil Nadu accounted for more than 80% of all active cases in India by the end of February. Except for Karnataka, vaccination coverage during the initial phase was less than the national average of 35% in each of these high burden states (Figure 1, Panel C). We estimated individuals eligible for the initial vaccination phase using state-level data on the number of health care work-. Vaccination uptake was positively correlated with vaccine delivery infrastructure such that the states that had a higher number of vaccination clinics per 1000 eligible individuals were able to achieve higher vaccination coverage by the end of the initial phase of vaccination (Figure 2, Panel B, P < 0.010). Vaccine safety and skepticism about the efficacy of the Covaxin vaccine that was approved before the completion of the Phase III clinical trial [7]
Sign-in/Register to view highlights & summary 
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
